OTHER MAP-K PATHWAY DRIVEN DISEASES

Clinical trials for OTHER MAP-K PATHWAY DRIVEN DISEASES explained in plain language.

Never miss a new study

Get alerted when new OTHER MAP-K PATHWAY DRIVEN DISEASES trials appear

Sign up with your email to follow new studies for OTHER MAP-K PATHWAY DRIVEN DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Last-Resort drug access opens for rare tumor patients

Disease control AVAILABLE

This program provides mirdametinib to individual patients with severe, life-threatening neurofibromatosis type 1 (NF1) or other MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. The goal is to control the disease when standard therapies …

Matched conditions: OTHER MAP-K PATHWAY DRIVEN DISEASES

Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control

Last updated May 26, 2026 12:12 UTC

OTHER MAP-K PATHWAY DRIVEN DISEASES

Get alerted when new OTHER MAP-K PATHWAY DRIVEN DISEASES trials appear

Last-Resort drug access opens for rare tumor patients